Originalien im "peer-review" Verfahren
Malessa R, Agelink MW, Diener HC. Dysfunction of visual pathways in HIV-1 Infection. J Neurol Sci 1995, 130: 82-87.
Malessa R, Agelink MW, van Schayck R, Mertins L, Brockmeyer NH. Elektrodermale Reflexaktivität und 30:15 Ratio bei HIV-1 Infektion. Akt Neurol 1995, 22: 131-135.
Dammers S, Zeit T, Leonhardt M, Schär V, Agelink MW. Malignes neuroleptisches Syndrom. Dtsch med Wschr 1995, 120: 1739-1742.
Malessa R, Agelink MW, Himmelmann M, Kloss T, Mertins L, Brockmeyer NH. Nerve conduction changes in asymptomatic HIV-1 seropositive individuals in the ab-sence of other risk factors for neuropathy. Electromyogr Clin Neurophysiol 1996, 36: 3-8. Agelink MW, Dammers S, Zeit T.
Clonidin- Abususrisiko beipsychisch kranken Patienten?Nervenarzt 1996, 67: 253-255.
Malessa R, Ohrmann P, Agelink MW, Brockmeyer NH, Diener HC. HIV-1-assoziierte autonome Dysfunktion (HIVAD). Nervenarzt 1996, 67: 147-154.
Malessa R, Agelink MW, Hengge U, Mertins L, Gastpar M, Brockmeyer NH. Oligosymptomatic neurosyphilis with false negative CSF-VDRL in HIV-infected individuals? Eur J Med Res 1996, 1: 299-302. Agelink MW, Zitzelsberger A, Klieser E. Withdrawal syndrome after discontinuation of venlafaxine. Am J Psychiatry 1997, 154: 1473-1474. Agelink MW, Dammers S, Malessa R, Leonhardt M, Zitzelsberger A, Ullrich H,
T. Nutzen und Risiken derElektrokrampfbehandlung beiälteren Patienten mitkardiovaskulären Risikofaktoren. Nervenarzt 1998, 69: 70-75. Agelink MW, Dirkes-Kersting A, Zeit T, Bertling R, Malessa R, Klieser E. Sensitivity of carbohydrate deficient transferrin (CDT) in relation to age and duration of abstinence. Alcohol & Alcoholism 1998, 33: 164-167. Agelink MW, Malessa R, Kamcili E, Zeit T, Lemmer W, Bertling R, Klieser E. Cardiovascular autonomic reactivity in schizophrenics under neuroleptic treatment: A potential predictor of short term outcome? Neuropsychobiology 1998, 38: 19-24. Agelink MW, Malessa R, Weisser U, Lemmer W, Zeit T, Majewski T, Klieser E. Alcoholism, peripheral neuropathy (PNP) and cardiovascular autonomic neuropathy (CAN). J Neurol Sci 1998, 161: 135-142. Agelink MW, Malessa R, Lemmer W, Zeit T, Majewski T, Klieser E. Improved autonomic neurocardial balance in short term abstinent alcoholics treated with acam-prosate. Alcohol & Alcoholism 1998, 33: 602-605. Agelink MW, Zeit T, Klieser E. Prolonged bradycardia
complicated combined venlafaxineand electroconvulsive therapy. Br JPsychiatry 1998, 173: 441. Agelink MW, Ullrich H, Lemmer W, Dirkes-Kersting A, Zeit T. Screening for concomitant alcohol abuse in schizophrenia: Clinical significance of the Munich Alco-holism Test and laboratory parameters. Eur Addict Res 1999, 5: 82-87.
Wurthmann C, Gregor J, Agelink MW, Effenberger O, Baumann B, Döhring W, Bogerts B. Morphometrische Untersuchung der Hirnmorphologie bei Agoraphobien. Psycho 2000, 26: 451-454.
Postert T, Lack B, Kuhn W, Jergas M, Andrich J, Braun B, Przuntek H, Sprengelmeyer R, Agelink MW, Büttner T. Basal ganglia alterations and brain atrophy in Huntington`s disease depicted by transcranial real time sonography. J Neurol Neurosurg Psychiatry 1999, 67: 457-462. Agelink MW, Majewski T, Wurthmann C, Lukas K, Ullrich H, Linka T, Klieser E. Effects of newer atypical antipsychotics on autonomic neurocardiac function: A comparison between
amisulpride, olanzapine, sertindoleand clozapine. J ClinPsychopharmacol 2001, 21: 8-13. Agelink MW, Majewski T, Wurthmann C, Postert T, Linka T, Rotterdam S, Klieser E. Autonomic neurocardiac function in patients with major depression and effects of antidepressive treatment with nefazodone. J Affect Dis 2001, 62: 187-198.
Eich H, Agelink MW, Lemmer W, Lehmann E, Klieser E. Akupunktur bei leichten bis mittelschweren depressiven Episoden und Angststörungen: Ergebnisse einer experimentiellen Untersuchung. Fortschr Neurol Psychiat 2000, 68: 137-144. Agelink MW, Zeit T, Baumann B, Majewski T, Lemmer W, Postert T, Lukas K, Klieser E. In vivo cardiovascular effects of the new atypical neuroleptic sertindole. Int J Psychiatry Clin Pract 2001, 5: 33-40. Agelink MW, Malessa R, Baumann B, Majewski T, Akila F, Zeit T, Ziegler D. Standardized tests of heart rate variability (HRV): Normal ranges obtained from 309 healthy humans and effects of age,
gender and heart rate. ClinAutonom Res 2001; 11:99-108. Agelink MW, Majewski T, Andrich J, Mück-Weymann M. Short term effects of intravenous benzodiazepines on autonomic neurocardiac regulation in man. A comparison between midazolam, diazepam and lorazepam. Crit Care Med 2002; 30: 997-1006. Agelink MW, Andrich J, Postert T, Würzinger U, Zeit T, Klotz P, Przuntek H. Relationship between electroconvulsive therapy (ECT), cognitive side effects, neuron-specific enolase and protein S-100. J Neurol Neurosurg & Psychiatry 2001; 71:394-396. Agelink MW, Brockmeyer N, Ullrich H. Sildenafil does not influence autonomic neurocardiac control assessed by standard measurements of heart rate variability Circulation 2001; 104: pE145. Agelink MW, Ullrich H, Baumann B, Strum S, Majewski T. Effects of reboxetine, a selective norepinephrine re-uptake inhibitor, on sympathetic and parasympathetic outflow to the heart. Psychopharmacology 2002; 163: 151-156.
Andrich J, Schmitz T, Saft, C,Bingöl HR, Kraus P, Epplen JT,Przuntek H,
Agelink MW.
Autonomic nervous systemfunction in Huntington Disease. JNeurol Neurosurg & Psychiatry2002; 72: 726-731.
Mück-Weymann M, Acker J, Agelink MW. Autonomic responses of blood vessels and sweat glands in patients with schizophrenia treated with olanzapine or clozapine. Psychopharmacology 2001; 157: 368-372. Agelink MW, Schmitz T, Rembrink K, Beckerling D, Mück-Weymann M, Brockmeyer NH. Cardiovascular effects of sildenafil citrate (viagraÒ):A naturalistic cross-over study. Eur J Med Res 2001; 6: 459-464.
Baumann B, Bielau H, Krell D, Agelink MW, Diekmann S, Wurthmann C, Trübner K, Bernstein HG, Danos P, Bogerts B. (mit Unterstützung der Deutschen Forschungsgemeinschaft - DFG 799/6-1 - und dem Ministerium für Bildung und Forschung - BMBF 01 ZZ 9510-). Circumscribed numerical deficit of dorsal raphe neurons in mood disorders. Agelink MW, Boz C, Ullrich H, Andrich J. Relationship between major depression and heart rate variability. Clinical consequences and implications for antidepressive treatment. Psychiatry Res 2002; 113: 139-149 Agelink MW. Prolongation of QTc interval and antipsychotics. Am J Psychiatry 2002; 159:1063. Agelink MW, Ullrich H, Passenberg P, Sayar K, Brockmeyer NH. Superior safety of reboxetine over amitryptiline in the elderly: a case report. Eur J Med Res 2002; 7: 415-416.
Mück-Weymann M, Moesler T, Joraschky P, Rebensburg M, Agelink MW. Depression modulates autonomic cardiac control: a physio-psychological pathway linking depression and mortality. German J Psychiatry 2002; 5: 67-69. Agelink MW, Sanner D, Eich H, Pach J, Bertling R, Lemmer W, Klieser E, Lehmann E. Beeinflußt
Akupunktur die autonom kardialeRegulation bei Patienten mitleichten depressiven Episodenoder Angststörungen? FortschrNeurol Psychiat; 2003; 71:141-149. Agelink MW, Sayar K, Klieser E. Usefulness of heart rate variability (HRV) for monitoring clozapine plasma levels. Pharmacopsychiatry 2003; 36: 166-167.
Kavuk I, Yavuz A, Cetindere Ü, Agelink MW, Diener HC. Epidemiology of chronic daily headache. Eur J Med Res 2003; 8: 236-240
Ullrich H, Passenberg P. Agelink MW. Depressive Störung mit Suizidversuch nach Einnahme von Valsartan-Hydrochlorothiazid. Deutsch Med Wochenschr (DMW) 2003; 128: 2534-2536
Loeffler S, Fehsel K, Henning U, Fischer J, Agelink MW, Kolb-Bachofen V,
Increased apoptosis of neutrophilsin a case of clozapine-inducedagranulocytosis. Pharmacopsychiatry 2003; 36:37-41.
Kavuk I, Agelink MW, Gaertner T, Kastrup O, Doerfler A, Maschke M, Diener HC. Wernicke`s encephalopathy: unsual contrast enhancement revealed by magnetic resonance imaging. Eur J Med Res 2003; 8: 492-494
Kämpf P, Agelink MW, Maß R, Jahn H, Schäfer I, Naber D. Amisulpride in addition to clozapine: a retrospective study indicates improved efficacy and good tolerability. German J Psychiatry 2003; 6: 64-68 Agelink MW, Baumann B, Sanner D, Kavuk I, Mück-Weymann M. Komorbidität zwischen kardiovaskulären Erkrankungen und Depressionen. Deutsch Med Wochenschr (DMW) 2004; 129: 697-700
Kavuk I, Katsarava Z, Stang A, Agelink MW, Limmroth V, Diener HC. Neues zur Epidemiologie von Kopfschmerzen. Fortschr Neurol Psychiatr 2004; 72: 184-191 Agelink MW, Klimke A, Cordes J, Sanner D, Kavuk I, Malessa R, Klieser E, Baumann B. A
functional-structural model tounderstand cardiac autonomicnervous system (ANS)dysregulation in affective illnessand to elucidate the ANS effects ofantidepressive treatment. Eur JMed Res 2004; 9: 37-50
Agelink MW, Kavuk I, Ak I. Clozapine combined with amisulpride for refractory schizophrenia: a retrospective analysis of 7 cases. Am J Psychiatry 2004; 924-925 Agelink MW, Baumann B, Sanner D, Kavuk I, Mück-Weymann M. Komorbidität zwischen kardiovaskulären Erkrankungen und Depressionen. PsychoNeuro 2004; 30: 541-547
Andrich J, Saft C, Arz A, Schneider B, Agelink MW, Kraus PH, Kuhn W, Muller T. Hyperhomocysteinaemia in treated patients with Huntington’s disease. Mov Disord 2004; 19: 226-228
Kavuk I, Koeppen S, Agelink MW, Doerfler A, Limmroth V, Diener HC. Transient MRI abnormalities associated with partial status epilepticus. J Neurol 2004; 251: 1156-1157
Kavuk I, Yavuz A, Cetindere U, Agelink MW, Diener HC. Chronic headache: a focus on medication overuse. Eur J Med Res 2004; 9: 285 Nach Einreichen der Habilitationsschrift
Cordes J, Streit M, Loeffler S, Wilmsdorff M, Agelink MW, Klimke A. Reversible neutropenia during treatment with olanzapine: three case reports. World J Biol Psychiatry 2004; 5: 230-234
Selekler HM, Kavuk I, Agelink MW, Komsuoglu S. Questioning aggravation of headache during migraine attacks. Eur J Med Res 2004; 9: 279-281
Kavuk I, Katsarava Z, Selekler M, Sayar K, Agelink MW, Limmroth V, Diener HC. Clinical features and therapy of medication overuse headache. Eur J Med Res 2004; 9: 565-569
Kämpf P, Agelink MW, Naber D. Augmentation of clozapine with amisulpride. Pharmacopsychiatry 2005; 38: 39-40
Cordes J, Mobascher A, Arends M, Agelink MW, Klimke A. Ein neues Behandlungsverfahren der Depression: Die repetitive transkranielle Magnetstimulation (rTMS). Deutsch Med Wochenschr 2005; 130: 889-892
Bielau H, Mawrin C, Krell D, Agelink MW, Truebner K, Davis R, Gos T, Bogerts B, Bernstein HG, Baumann B. Differences in activation of the dorsal raphe nucleus depending on performance of suicide. Brain Res 2005; 1039: 43-52
Kavuk I, Hufnagel A, Agelink MW, Limmroth V, Dörfler A, Sayar K, Selekler M, Diener HC, Koeppen S. MRI changes with associated with partial status epilepticus. Eur J Med Res 2005; 10: 243-246
Mobascher J, Zielasek J, Schuier FJ, Mobascher A, Grohmann R, Agelink MW, Cordes J. Guillan-Barre-syndrome after septicemia following clozapine-induced agranulocytosis. Pharmacopsychiatry 2005; 38: 329-330
Bielau H, Truebner K, Krell D, Agelink MW, Bernstein HG,
Stauch R, Mawrin C, Danos P,Gerhard L, Bogerts B, Baumann B. Volume deficits of subcorticalnuclei in mood disorders: a postmortem study. Eur Arch PsychiatryClin Neurosci 2005; 255: 401-412.
Siepmann M, Joraschky P, Rebensburg M, Rittger H, Mösler T, Agelink MW, Mück-Weymann M. Ist die autonome kardiale Regulation bei Patienten mit Depression und koronarer Herzerkrankung gestört? Zeitschr Klin Psychol Psychother 2005;34:277-281
Blaschke S, Kornischka J, Agelink MW. Deutliche Gewichtsreduktion nach Aripiprazol. Nervenheilkunde 2005; 24: 426-427
Fehsel K, Loeffler S, Krieger K, Henning U, Agelink MW, Kolb-Bachofen V, Klimke A. Clozapine induces oxidative stress and proapoptotic gene expression in neutrophils of schizophrenic patients. J Clin Psychopharmacol 2005; 25: 419-426
Cordes J, Klimke A, Kornischka J, Agelink MW, Hauner H. Therapie der Schizophrenie mit Antipsychotika: Gewichtszunahme ist ein relevanter Faktor. Der
Neurologe & Psychiater (DNP)2006: 1-2: 45-51.
Cordes J, Arends M, Mobascher A, Brinkmeyer J, Kornischka J, Eichhammer P, Klimke A, Winterer G, Agelink MW. Potential clinical targets of repetetive transcranial magnetic stimulation treatment in schizophrenia. Neuropsychobiology 2006; 54: 87-99 Agelink MW, Kornischka J, Cordes J, Klimke A, Hauner H, Ziegler D. Allgemeinmedizinische Aspekte der Therapie mit Antipsychotika der zweiten Generation. Deutsches Ärzteblatt 2006; 2437-2443
Kornischka J, Cordes J, Agelink MW. 40 Jahre Beta-Blocker in der Psychiatrie: Eine systematische Übersicht. Fortschr Neurol Psychiatr 2007; 75: 199-210
Kornischka J, Assion HJ, Machleidt K, Agelink MW. Psychische und psychosoziale Probleme bei Spätaussiedlern. Psychiatr Prax 2008; 35: 60-66.
Baer J, Wernich K, Boettger S, Cordes J, Boettger MK, Loeffler S, Kornischka J, Agelink MW. Relationship between cardiovagal modulation and psychotic state in patients with schizophrenia. Psychiatry Res 2008; 157: 255-257.
Luckhaus, C, Hennersdorf M, Bell M, Agelink MW, Zielasek J, Cordes J. Brugada-syndrom as a potential cardiac risk factor during electroconvulsive therapy. World J Biol Psychiatry 2008; 9: 150-153
Stirban A, Laude D, Elghozi JL, Sander D, Agelink MW, Hilz MJ, Ziegler D. Acute effects of sildanefil on flow mediated dilatation and cardiovascular autonomic nerve function in type-2 diabetic patients. Diabetes Metab Res Rev 2009; 25: 136-143.
Siepmann M, Rauh R, Dill O, Agelink MW, Mück-Weymann M. The effects of sildenafil on heart rate variability in healthy subjects. J Cardiovasc Pharmacol 2007; 50: 598-600.
Baer KJ, Boettger MK,Andrich J, Epplen JT,Fischer F, Cordes J, Koschke M, Agelink MW. Cardiovagal modulation upon postural change is altered in Huntington´s disease. J Neurol Neurosurg and Psychiatry 2008; 15: 869-871
Baer KJ, Boettger MK, Schulz S, Harzendorf C, Agelink MW, Yeragani VK, Chokka P, Voss A. The interaction between pupil function and cardiovascular regulation in patients with acute schizophrenia. Clin Neurophysiol 2008; 119: 2209-2213.
Boettger MK, Baer KJ, Dohrmann A, Müller H, Mertins L, Brockmeyer NH, Agelink MW.Increased vagal modulation in atopic dermatitis. J Dermatol Sci 2009; 53: 55-59.
Cordes J, Sinha-Röder A, Kahl KG, Malevani J, Thuenker J, Lange-Asschenfeldt C, Hauner H, Agelink MW, Klimke A. Therapeutische Optionen für ein Gewichts-managementprogramm bei mit atypischen Antipsychotika behandelten schizophrenen Patienten. Fortschr Neurol Psychiatr 2008; 76: 703-714.
Mobascher A, Arends M,Eschweiler GW, Brinkmeyer J,
Agelink MW, Kornischka J, Winterer G, Cordes J. Biological correlates of prefrontal activating and temperoparietal inhibiting treatment with repetitive transcranial magnetic stimulation (rTMS). Fortschr Neurol Psychiatr 2009; 77; 432-443.
Mittrach M, Thünker J, Winterer G, Agelink MW, Regenbrecht G, Arends M, Mobascher A, Kim SJ, Wölwer W, Brinkmeyer J, Gaebel W, Cordes J. The tolerability of rTMS treatment in schizophrenia with respect to cognitive function. Phramacopsychiatry 2010; 43: 110-117.
Baer KJ, Ebert A, Boettger MK, Merz S, Kiehntopf M, Jochum T, Juckel G, Agelink MW. Is successful electroconvulsive therapy (ECT) related to stimulation of the vagal system? J Affect Disord 2010; 125: 323-329.
Cordes J, Thünker J, Agelink MW, Arends M, Mobascher A, Wobrock T, Schneider-Axmann T, Brinkmeyer J, Mittrach M, Regenbrecht G, Wölwer „W, Winterer G, Gaebel W. Effects of 10Hz repetitive transcranial magnetic stimulation (rTMS) on clinical global impression in chronic schizophrenia. Psychiatr Res 2010; 177: 32-36.
A d v a n ci n g W h y a l l a I n v i t es Where: Westlands Hotel (Oasis Function L i gh t R ef r esh m en t s P r ov i d ed / B a r op en IN SID E TH IS ISSU E: Email: advwhy@centralonline.com.au The evening will feature a presentation from Yolie Entsch who will also facili-tate a brainstorming activity and feedback forum. Yolie is a highly respected motivational speaker with
BöttcherFount S-3007 Fountain Solution Additive for IPA-free printing BöttcherFount S-3007 is a fountain solution additive for sheet-fed printing and for continuous form printing, particularly for alcohol-free printing. For IPA-free printing or IPA reduction 0 - 5% pH-value 4,9 - 5,5 (depends on hardness of water) suitable for water hard